Considerations for regulation and evaluation of digital mental health technologies
Rattachement africain : gb. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Digital mental health technologies (DMHTs) are becoming well established within mental health services and through direct-to-consumer models. Due to their scalable nature, DMHTs may support services to bridge the gap between demand and the available workforce, particularly where existing pathways have long delays or restricted capacity. Challenges and risks associated with DMHTs also need consideration. Regulatory and health technology assessment (HTA) agencies play a key role in ensuring the potential of DMHTs is achieved and their risks are mitigated. However, the nature of DMHTs and advances in digital technology present challenges for regulation and evaluation. In this paper, we describe eight key considerations across the regulatory and HTA pathway for DMHTs. These relate to 1) intended purpose, 2) qualification and classification, 3) risk management, 4) clinical evidence, 5) resource requirements and economic evidence, 6) post-market surveillance and life cycle assessment, 7) replicability and equity, and 8) wider responsibilities. Ensuring clarity within these considerations and addressing outstanding uncertainties is necessary to ensure that the benefits of DMHTs are unlocked, while also ensuring that people have access to high quality and safe tools.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Considerations for regulation and evaluation of digital mental health technologies
- Date Crossref
- 01/01/2024
- Éditeur
- SAGE Publications
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
National Institute for Health and Care Excellence Science Evidence and Analytics Directorate pays non établi dans la noticeOrganisme public
-
Informa Healthcare pays non établi dans la noticeÉtablissement de santé
-
Medicines and Healthcare products Regulatory Agency Healthcare Quality and Access Group pays non établi dans la noticeOrganisme public
Science Evidence and Analytics Directorate — National Institute for Health and Care Excellence, Informa Healthcare et Healthcare Quality and Access Group — Medicines and Healthcare products Regulatory Agency.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.